The sharing of even identified dataset of this study is restricted by Biobank Law of Finland (688/2012, Biobank Act: <http://www.finlex.fi/fi/laki/kaannokset/2012/en20120688.pdf>, see especially sections 26-27). To summarize, the dataset and samples encoded to defined projects can only be requested through permit authorization process from Auria Biobank for justifiable research projects (<https://www.auriabiopankki.fi/?lang=en>).

Introduction {#sec001}
============

Five-year survival in stage II colorectal cancer (CRC) is 70--80% \[[@pone.0185436.ref001],[@pone.0185436.ref002]\]. Unfavorable prognostic factors for stage II CRC include lymphovascular invasion, less than 12 examined lymph nodes, poor differentiation grade, tumor spreading to the peritoneum or adjacent tissue structures as well as tumor obstruction or perforation. \[[@pone.0185436.ref003],[@pone.0185436.ref004]\]. These risk factors have been utilized in the assessment of stage II colorectal cancer patients in need of postoperative adjuvant treatments. The benefit of chemotherapy in stage III colorectal cancer patients is apparent, but controversial in stage II colorectal cancer patients even with above-mentioned risk factors \[[@pone.0185436.ref005]\]. Consequently, there is a crucial need to discover new markers to better define those at highest danger of disease recurrence.

DNA mismatch repair competence is a feature associated with CRC outcome. Inactivation of genes responsible for mismatch repair competence cause microsatellite instability (*MSI*), which can be studied by expression of the gene products MLH1, MSH2, MSH6 and PMS2 or by PCR-based methods \[[@pone.0185436.ref006],[@pone.0185436.ref007],[@pone.0185436.ref008],[@pone.0185436.ref009],[@pone.0185436.ref010],[@pone.0185436.ref011]\]. *MSI* is reported in about 15--20% of CRC \[[@pone.0185436.ref008],[@pone.0185436.ref012]\]. *MSI* is linked to right-sided, poorly differentiated tumors with higher T stage and younger patient age \[[@pone.0185436.ref012]\]. Stage II CRCs with *MSI*, as demonstrated by immunohistochemistry of mismatch repair proteins, have a more favorable prognosis as compared to microsatellite stable (*MSS*) tumors \[[@pone.0185436.ref013],[@pone.0185436.ref014],[@pone.0185436.ref004]\]. Moreover, patients with defective mismatch repair (dMMR) stage II tumors do not seem to benefit from fluorouracil-based adjuvant chemotherapy \[[@pone.0185436.ref015],[@pone.0185436.ref016]\]. *MSI* tumor can evolve in Lynch syndrome patients carrying a germ-line mutation in one MMR gene, or through sporadic events involving epigenetic silencing of the *MLH1* gene \[[@pone.0185436.ref017]\].

*BRAF* gene encodes a protein kinase of the *RAS/RAF/MEK-ERK* signaling cascade, which is regulated by *KRAS* \[[@pone.0185436.ref018],[@pone.0185436.ref019]\]. Previously, *BRAF* V600E mutation was shown to be an adverse prognostic factor for overall survival in stage II-III colon cancer \[[@pone.0185436.ref020]\]. *MSS* together with *BRAF* mutation is associated with poor prognosis in CRC \[[@pone.0185436.ref009],[@pone.0185436.ref021]\]. On the contrary, *MSI* stage II tumors with *BRAF V600E* mutation are associated with a rather favorable prognosis \[[@pone.0185436.ref021]\]. Moreover, colorectal cancer with *MSI* phenotype and a concomitant *BRAF* mutation indicates a sporadic tumor, thus excluding Lynch syndrome \[[@pone.0185436.ref017],[@pone.0185436.ref021]\].

Ezrin is a cytoskeleton-associated protein, which participates in cellular signaling, cell survival, proliferation and migration. Its association with malignant behavior has been suggested in several experimental models, and in several cancers strong ezrin expression correlates with inferior outcome. \[[@pone.0185436.ref022],[@pone.0185436.ref023],[@pone.0185436.ref024],[@pone.0185436.ref025],[@pone.0185436.ref026],[@pone.0185436.ref027],[@pone.0185436.ref028]\]. Our previous work has demonstrated the impact of ezrin expression on the outcome in metastatic CRC as well as in localized rectal cancer \[[@pone.0185436.ref027],[@pone.0185436.ref028]\]. To our knowledge, the role of ezrin as a prognostic marker in stage II colorectal cancer has not been studied before.

In this work, we utilized tumor tissue collection form consecutive stage II CRC patients, together with extensive clinical, disease outcome and follow-up data to search for tissue-based prognostic markers. We report the association of *MSI* status, *BRAF* mutation status and ezrin protein expression with clinicopathological variables and patient outcome. Our results suggest that combined *MSI* and ezrin analysis can stratify tumors according to their clinical behavior.

Patients and methods {#sec002}
====================

Study population {#sec003}
----------------

We collected archived paraffin-embedded tumor material from consecutive stage II CRC patients operated in Turku University Hospital in 2005--2012. This study was approved by Chief Executive Officer of TYKS-SAPA, Hospital District of Southwest Finland (T52/2014). The use of tissue material was approved by Scientific Steering Group of Auria Biobank (AB15-8108, 25.5.2012). The study was conducted in accordance with the Declaration of Helsinki. The clinical data were retrieved and histological samples collected and analyzed with the endorsement of the National Authority for Medico-Legal Affairs (VALVIRA). The patient records were accessed anonymously.

In 2005--2012 a total of 232 stage II CRC patients were radically operated in our hospital. Computed tomography (CT) of the abdomen and chest x-ray or CT had been performed preoperatively to rule out distant metastases. We carefully checked the patient files, including surgery and pathology reports and excluded patients with verified lymph node or distant metastases, those who had been operated with palliative-intent surgery, and also patients with other than adenocarcinoma histology (e.g. neuroendocrine tumors). Only patients with stage II CRC were included in the current study. For tumor staging, TNM7 classification of malignant tumors \[[@pone.0185436.ref029]\] was used. From the original cohort (n = 232), tumor material for *MSI* staining was available from 214 patients. For further BRAF and ezrin stainings, material was available from 173 patients. These patients (n = 173) were included in statistical analyses.

TMA construction {#sec004}
----------------

Tissue microarrays (TMA) were constructed and analyzed using the next-generation TMA technique \[[@pone.0185436.ref030]\]. Shortly, the appropriate formalin-fixed paraffin-embedded (FFPE) tissue specimens were chosen based on clinical data and retrieved from the pathology archives. A representative hematoxylin-eosin (H&E) section containing areas of invasive carcinoma was selected from each tumor. New H&E slides were produced, scanned (Pannoramic P250, 3DHistech) and uploaded into the university digital microscopy web portal (casecenter.utu.fi). Each slide was viewed using Pannoramic Viewer software (3DHistech). Using the 1.2 mm diameter annotation tool, annotations of different colors corresponding to various histological areas were placed onto each digital slide. Two annotations were placed in the center of the tumor, two in the tumor front and two in the normal colonic epithelium. The corresponding tissue cores were then transferred into the TMA blocks using an automated TMA instrument (TMA Grandmaster, 3DHistech) by overlaying each annotated digital slide with the corresponding tissue specimen. One tissue core containing benign tissue was selected from each tumor to act as a control. The constructed TMA blocks were sectioned, stained, scanned and uploaded into the web portal (casecenter.utu.fi) and each individual spot was scored by two pathologists (KS, JS). The resulting scores were combined with the clinical data for statistical analysis.

Immunohistochemistry {#sec005}
--------------------

Immunohistochemical staining against MMR proteins is a useful screening method in research materials with paraffin-embedded TMA-samples. In contrast to PCR-based methods, it also readily provides information on the inactivated gene. Immunohistochemical stainings (IHC) were performed using standard procedures. Shortly, 3,5 μm sections were cut from the TMA blocks. They were stained with monoclonal antibodies against MLH1 (Clone G168-15BD Pharmingen, dilution: 1:5), MSH2 (Clone G219-1129, BD Pharmingen, dilution: 1:200) and MSH6 (Clone EP49, Epitomoc, dilution: 1:200). The signal was detected with UltraView Universal DAB Detection kit. For PMS2, Clone EPR3947 (Ventana/Roche, ready to use antibody) was used and the signal was detected with OptiView Universal DAB Detection Kit and amplification kit. To detect *BRAF V600E* mutation, BRAF RTU antibody (Clone VE1, Roche/Ventana) was used and the signal was detected with OptiView Universal DAB Detection kit. For ezrin staining, immunoglobulin G antibody to human ezrin (clone 3C12) \[[@pone.0185436.ref031]\] was used. All the stainings were performed with BenchMark XT (Ventana/Roche) using ultraVIEW Universal DAB Detection Kit (Ventana/Roche), except ezrin, which was done with LabVision immunoautomate (Thermo Fisher Scientific) using the Power Vision Plus poly HRP anti-mouse/rabbit/rat IgG detection kit.

Evaluation of immunohistochemical stainings {#sec006}
-------------------------------------------

All IHC stainings were separately evaluated by two observers (KS and JS), blinded to clinical data. For MLH1, MSH2, MSH6, PMS2 and ezrin, inflammatory cells of the stroma were used as positive controls. For analyses of *MSI* (MLH1, MSH2, MSH6 and PMS2) also the cores from normal colonic epithelium were used as positive controls. As a positive control in evaluating the BRAF-stainings, we used *BRAF V600E* mutation-positive cancer tissue obtained from a CRC patient who did not belong to this study cohort. These IHC stainings were evaluated dichotomously as positive or negative. For ezrin protein expression, cytoplasmic staining was recorded \[[@pone.0185436.ref027], [@pone.0185436.ref028]\].Four staining categories were used: 0 for negative staining, 1 for weak staining (distinguishable from the background staining), 2 for moderate staining and 3 for strong staining (corresponding to immunoreactivity in lymphocytes) \[[@pone.0185436.ref027]\]. In addition, a category of non-evaluable was used for all stainings. For statistical purposes a dichotomous grading, ezrin low (negative or weak staining) and ezrin high (moderate or strong staining) was used.

Statistical analysis {#sec007}
--------------------

Statistical analyses were performed with IBM SPSS version 23 with standard packages. Clinical data were analyzed in correlation with histological, immunohistochemical and mutational analysis data using χ^2^ or Fisher's exact-test for discrete variables and one-way ANOVA for continuous variables. Overall survival (OS), disease free survival (DFS) and disease-specific survival (DSS) were calculated using Kaplan-Meier curves. Survival was analyzed with respect to (stratified to) different biomarkers using log-rank test. For multivariate analyses, the following variables were used: tumor grade, tumor-side, obstruction, perforation, vascular invasion, *BRAF* mutated/wild type, ezrin low/high and *MSS/MSI* combinations were included. Multivariate Cox proportional hazard regression model was used to adjust the survival curves for covariates and to obtain estimates on hazard ratios. All p-values were two-sided, and values less than 0.05 were considered statistically significant.

Results {#sec008}
=======

General aspects of clinical patient characteristics {#sec009}
---------------------------------------------------

Altogether 173 patients were included in this study. The tumor was located in the proximal colon in 70 (40%), transverse colon in 19 (11%), descending colon in 8 (5%), sigmoid colon in 44 (25%) and rectum/rectosigmoideum in 32 (19%) patients. There were 30 (17%) T4-tumors included in the study. Vascular invasion was reported in 32 (18%) patients and preoperative bowel obstruction in 26 (15%) of patients. Adjuvant fluorouracil-based chemotherapy had been given to 51 (30%) patients. The median follow-up time was 57 months. At the latest follow-up data collection time point in September 2016, 116 patients (67%) were alive without CRC, 3 (2%) alive with CRC, 17 dead of CRC, 18 (10%) dead of other cancers and 19 (11%) dead of other causes than cancer. The clinical characteristics of the patients are shown in [Table 1](#pone.0185436.t001){ref-type="table"}.

10.1371/journal.pone.0185436.t001

###### The clinicopathological variables of the patient population included in the MSI, BRAF and Ezrin analyses (n = 173).

NA = not available, R0 = microscopically radical surgery, R1 macroscopically radical surgery, R2 macroscopically non-radical surgery.
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  Variable                                             n (%)
  ---------------------------------------------------- -----------
  **Gender**                                            
  Female                                               92 (53)
  Male                                                 81 (47)
  **Age**                                               
  \<70 years                                           66 (38)
  \>70 years                                           107 (62)
  **Postoperative stage**                               
  T3N0                                                 143 (83)
  T4aN0                                                17 (10)
  T4bN0                                                13 (7)
  **Tumor side**                                        
  Right                                                89(51)
  Left                                                 84 (48)
  **Tumor grade** (analyzed from surgical specimens)    
  G1                                                   19 (11)
  G2                                                   114 (66))
  G3                                                   40 (23)
  **Histology**                                         
  Conventional adenocarcinoma                          151 (87)
  Mucinous adenocarcinoma                              22 (13)
  **Vascular invasion**                                 
  Yes                                                  32 (18)
  No                                                   131 (76)
  NA                                                   10 (6)
  **Lymph node count**                                  
  ≥12 lymph nodes examined                             138 (80)
  \<12 lymph nodes examined                            35 (20)
  **Radicality**                                        
  R0                                                   162 (94)
  R1                                                   8 (5)
  R2                                                   3 (2)
  **Preoperative obstruction**                          
  Yes                                                  26 (15)
  No                                                   147 (85)
  **Tumor perforation**                                 
  Yes                                                  15 (9)
  No                                                   157 (91)
  NA                                                   1 (0)
  **Adjuvant chemotherapy**                             
  Yes                                                  51 (30)
  No                                                   121 (69)
  NA                                                   1(0)

General aspects of *MSI* staining {#sec010}
---------------------------------

The results of the *MSS/MSI* analysis in relation to clinicopathological variables are shown in [Table 2](#pone.0185436.t002){ref-type="table"}. Overall, 136 (79%) of the tumors were *MSS* and 37 (21%) were *MSI* high. *MSI* was significantly more common in the right-sided tumors (n = 30; 34%), as compared with the left-sided tumors (n = 7; 8%) (Pearson's chi-square test, p = 0.0001). *MSI* was infrequent in well-differentiated tumors (1/39, 3%), but common in tumors with poor differentiation grade (15/39, 40%). Ten out of 22 (45%) mucinous cancers presented *MSI*. *MSI* status in relation to clinic-pathological variables is presented in [Table 2](#pone.0185436.t002){ref-type="table"}.

10.1371/journal.pone.0185436.t002

###### *MSS/MSI* status in relation to clinicopathological variables (n = 173).

NA = not available, R0 = microscopically radical surgery, R1 = macroscopically radical surgery, R2 = macroscopically non-radical surgery, CRC = colorectal cancer.
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  Variable                       *MSS*      *MSI high*   Significance *(p)*
  ------------------------------ ---------- ------------ --------------------
  **Gender**                                             0.266
  Female                         69 (51)    23 (62)      
  Male                           67 (49)    14 (38)      
  **Age**                                   ** **        0.707
  Under 70 years                 53 (39)    13 (35)      
  Over 70 years                  83 (61)    24 (65)      
  **Postoperative stage**                                0.253
  T3N0                           115 (85)   28 (76)      
  T4aN0                          13 (10)    4 (11)       
  T4bN0                          8 (6)      5 (13)       
  **Tumor side**                                         **0.0001**
  Right                          59 (43)    30 (81)      
  Left                           77 (57)    7 (19)       
  **Tumor grade**                                        **0.010**
  G1                             18 (13)    1 (3)        
  G2                             93 (68)    21 (57)      
  G3                             25 (18)    15 (40)      
  **Histology**                                          **0.009**
  Conventional adenocarcinoma    124 (91)   27 (73)      
  Mucinous adenocarcinoma        12 (9)     10 (27)      
  **Vascular invasion**                                  0.383
  Yes                            28 (21)    4 (11)       
  No                             101 (74)   30 (81)      
  NA                             7 (5)      3 (8)        
  **Lymph node count**                                   0.646
  12 or more examined            107 (78)   31 (84)      
  Less than 12 examined          29 (21)    6 (16)       
  **Radicality of surgery**                              0.446
  R0                             128 (94)   34 (92)      
  R1                             5 (4)      3 (8)        
  R2                             3 (2)      0 (0)        
  **Preoperative obstruction**                           0.604
  Yes                            22 (16)    4 (11)       
  No                             114 (84)   33 (89)      
  **Tumor perforation**                                  0.797
  Yes                            11 (8)     4 (11)       
  No                             124 (91)   33 (89)      
  NA\*                           1 (1)      0 (0)        
  **Adjuvant chemotherapy**                              0.218
  Yes                            37 (27)    14 (38)      
  No                             99 (73)    22 (59)      
  NA\*                           0 (0)      1 (3)        
  **Disease-specific outcome**                           0.660
  Alive without CRC              93 (68)    23 (62)      
  Alive with CRC                 3 (2)      0 (0)        
  Dead of CRC                    13 (10)    4 (13)       
  Dead of other cancer           13 (10)    5 (13)       
  Dead of other causes           10 (7)     5 (13)       
  Dead cause unspecified         4 (3)      0 (0)        

General aspects of *ezrin* staining {#sec011}
-----------------------------------

The results of the ezrin stainings in relation to clinicopathological parameters are shown in [Table 3](#pone.0185436.t003){ref-type="table"}. Generally, in 135 (78%) tumors, ezrin staining intensity was scored as low, and in 38 (28%) as high. High ezrin expression was more common in *MSI* tumors (19/37, 51%) than in *MSS* tumors (19/134, 14%) (Pearson's chi-square test, p = 0.0001). There were no statistically significant differences in ezrin intensity according to clinicopathological variables, except for disease outcome (see below). Ezrin staining in relation to clinic-pathological variables is presented in [Table 3](#pone.0185436.t003){ref-type="table"}.

10.1371/journal.pone.0185436.t003

###### Ezrin expression in relation to clinicopathological variables (n = 173). CRC = colorectal cancer.

![](pone.0185436.t003){#pone.0185436.t003g}

  Variable                       Ezrin low   Ezrin high   Significance *(p)*
  ------------------------------ ----------- ------------ --------------------
  **Gender**                                              0.272
  Female                         60 (44)     21 (55)      
  Male                           75 (56)     17 (45)      
  **Age**                                    ** **        0.130
  Under 70 years                 56 (41)     10 (26)      
  Over 70 years                  79 (58)     28 (74)      
  **Postoperative stage**                                 0.634
  T3N0                           113 (84)    30 (79)      
  T4aN0                          13 (10)     4 10)        
  T4bN0                          9 (7)       4 (10)       
  **Tumor side**                                          0.141
  Right                          65 (48)     24 (63)      
  Left                           70 (52)     14 (37)      
  **Tumor grade**                                         0.119
  G1                             14 (10)     5 (13)       
  G2                             94 (70)     20 (53)      
  G3                             27 (20)     13 (34)      
  **Histology**                                           0.099
  Conventional adenocarcinoma    121 (90)    30 (79)      
  Mucinous adenocarcinoma        14 (10)     8 (21)       
  **Vascular invasion**                                   0.677
  Yes                            26 (19)     6 (16)       
  No                             100 (74)    31 (82)      
  NA                             9 (7)       1 (3)        
  **Lymph node count**                                    1.000
  12 or more examined            108 (80)    30 (79)      
  Less than 12 examined          27 (20)     8 (21)       
  **Radicality of surgery**                               0.568
  R0                             127 (94)    35 (92)      
  R1                             6 (4)       2 (5)        
  R2                             1 (1)       1 (3)        
  **Preoperative obstruction**                            0.607
  Yes                            19 (14)     7 (18)       
  No                             116 (86)    31 (82)      
  **Tumor perforation**                                   0.476
  Yes                            10 (7)      5 (13)       
  No                             124 (92)    33 (87)      
  NA\*                           1 (1)       0 (0)        
  **Adjuvant chemotherapy**                               1.000
  Yes                            40 (30)     11 (29)      
  No                             95 (70)     26 (68)      
  NA\*                           0 (0)       1 (3)        
  ***MSI status***                                        **0.001**
  *MSS*                          117 (87)    19 (50)      
  *MSI*                          18 (13)     19 (50)      
  ***BRAF status***                                       **0.001**
  *BRAF WT*                      121 (91)    25 (66)      
  *BRAF mutated*                 12 (9)      13 (34)      
  **Disease-specific outcome**                            **0.038**
  Alive without CRC              93 (69)     23 (61)      
  Alive with CRC                 3 (2)       0 (0)        
  Dead of CRC                    8 (6)       9 (24)       
  Dead of other cancer           16 (12)     2 (5)        
  Dead of other causes           11 (8)      4 (11)       
  Dead cause unspecified         4 (3)       0 (0)        

BRAF staining {#sec012}
-------------

BRAF staining was available from 171 patients. Of the tumors, 146 (85%) were *BRAF wild type* and 25 (15%) *BRAF V600E mutated*. The *BRAF mutated* tumors predominantly presented with *MSI* (21/25, 84%), whereas *BRAF wild type* tumors were mostly *MSS* (130/146, 89%). Of the *BRAF wild type* tumors only 25/146 (17%) showed high ezrin IHC, while 13/25 (52%) of *BRAF mutant* tumors were ezrin high (Pearson's chi-square test, p = 0.0001). Combinatorial analysis of the three variables showed that *BRAF wild type* tumors were predominantly *MSS* / low ezrin (112/146, 77%), whereas 12/25 (48%) of the *BRAF mutated* tumors were *MSI /* high ezrin (Fisher's exact test, p = 0.0001). Follow-up data according to BRAF status is presented in [Table 4](#pone.0185436.t004){ref-type="table"}.

10.1371/journal.pone.0185436.t004

###### BRAF status in relation to ezrin and MSS/MSI (n = 171).
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  Variable               Ezrin MSS/Ezrin/MSI   Significance                                                        
  ---------------------- --------------------- --------------------- ---------------------- ---------------------- ----------------
                         ***Ezrin low MSS***   ***Ezrin low MSI***   ***Ezrin high MSS***   ***Ezrin high MSI***   **p = 0.0001**
  **n (%)**              **n (%)**             **n (%)**             **n (%)**                                     
  ***BRAF mutated***     3 (3)                 9 (50)                1 (5)                  12 (63)                
  **n (%)**                                                                                                        
  ***BRAF wild type***   112 (97)              9 (50)                18 (95)                7 (37)                 
  **n (%)**                                                                                                        

Clinical correlations {#sec013}
---------------------

The clinical correlations of the *MSI* status and ezrin staining are shown in Tables [2](#pone.0185436.t002){ref-type="table"} and [3](#pone.0185436.t003){ref-type="table"}. Altogether, high ezrin staining correlated with inverse DSS (Fisher's exact test, p = 0.038). On the other, *MSI* status as a single variable did not correlate with survival. In categorical analysis of 5-year disease-specific survival time, 11 out of 18 (61%) patients with *MSI* / low ezrin were alive compared to only 4 out of 18 (21%) patients with *MSS* / high ezrin (Fisher's exact test, p = 0.040). In univariate analysis, patients whose tumors were *MSI* / low ezrin tended to have the best OS probability, and those with *MSI* / high ezrin the worst, but the difference was not statistically significant (log-rank test, p = 0.235). Patients with *MSI* / low ezrin tumors had the longest DSS and those with *MSS* / high ezrin tumors had the shortest (log-rank test, p = 0.007). An example of staining patterns of patients belonging to groups of best and worst DSS are presented in Figs [1](#pone.0185436.g001){ref-type="fig"} and [2](#pone.0185436.g002){ref-type="fig"}, respectively. Patients with *MSI* / low ezrin had the longest DFS and those with *MSI* / high ezrin had the shortest, but the difference was no statistically significant (log-rank test, p = 0.069). The survival curves are presented in [Fig 3](#pone.0185436.g003){ref-type="fig"} and the results of univariate survival analysis in [S1 Table](#pone.0185436.s001){ref-type="supplementary-material"}.

![An example of a tumor with *MSI*-high features and weak ezrin expression.\
MLH1 (A) and PMS2 (B) are negative in nuclei of cancer cells, while MSH2 (C) and MSH6 (D) show normal nuclear staining. Tumor cells show weak immunostaining for ezrin (E). This patient had a favorable prognosis.](pone.0185436.g001){#pone.0185436.g001}

![An example of a tumor with MSS features and strong ezrin expression.\
MLH1 (A), PMS2 (B), MSH2 (C) and MSH6 (D) show normal nuclear staining in colorectal cancer cells. Tumor cells show strong immunostaining for ezrin (E). This patient had an unfavorable outcome.](pone.0185436.g002){#pone.0185436.g002}

![Kaplan-Meyer survival analysis of stage II colorectal cancers based on *MSI* status and ezrin expression.\
Disease-specific survival (A) and disease-free survival (B).](pone.0185436.g003){#pone.0185436.g003}

A summary of the multivariate analyses results is presented in [Table 5](#pone.0185436.t005){ref-type="table"}. This table shows T4bN0 tumors to be associated with inferior OS (Cox model, HR 2.86, 95% CI \[1.06--7.74\], p = 0.038) and DFS (Cox model, HR 8.05, 95% CI \[2.31--28.01\], p = 0.001). Likewise, perforation was linked to inferior OS (Cox model, HR 3.8, 95% CI \[1.57--9.17\], p = 0.003), DSS (Cox model, HR 5.44, 95% CI \[95% CI 1.3--22.75\], p = 0.02), as well as DFS (Cox model, HR 4.87 95% CI \[1.38--17.23\]; p = 0.014). Moreover, the presence of *BRAF* mutation was associated to shortened OS (Cox model, HR 3.29, 95%CI \[1.14--9.54\], p = 0.028). High ezrin expression together with *MSS* were linked to shorter DSS (Cox model, HR 5.68, 95%CI \[1.53--21.12\], p = 0.01).

10.1371/journal.pone.0185436.t005

###### Summary of the results in multivariate analysis.
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  Variable (n)                  Overall survival     Disease-specific survival   Disease-free survival                                                         
  ----------------------------- -------------------- --------------------------- ----------------------- ------ ------------- ----------- ------ ------------- -----------
  **Stage T3N0 (143)**          Reference category   Reference category          Reference category                                                            
  **Stage T4aN0 (17)**          1.76                 0.64--4.83                  0.275                   3.40   0.72--15.98   0.121       3.04   0.82--11.33   0.097
  **Stage T4bN0 (13)**          2.86                 1.06--7.74                  **0.038**               4.58   0.89--23.62   0.069       8.05   2.31--28.01   **0.001**
  **Grade 1 (19)**              Reference category   Reference category          Reference category                                                            
  **Grade 2 (114)**             0.50                 0.20--1.29                  0.153                   0.93   0.13--6.56    0.946       0.82   0.13--5.21    0.838
  **Grade 3 (40)**              0.53                 0.18--1.53                  0.241                   0.68   0.08--6.12    0.732       1.27   0.18--8.87    0.809
  **Right colon (89)**          1.35                 0.69--2.65                  0.378                   1.27   0.37--4.36    0.702       1.04   0.39--2.83    0.933
  **Vascular invasion (19)**    1.57                 0.78--3.18                  0.210                   3.36   0.98--11.57   0.055       3.62   1.26--10.37   **0.017**
  **Perforation (10)**          3.80                 1.57--9.17                  **0.003**               5.44   1.3--22.75    **0.002**   4.87   1.38--17.23   **0.014**
  **Preop. obstruction (19)**   0.71                 0.27--1.85                  0.479                   1.32   0.31--5.65    0.71        1.53   0.45--5.21    0.499
  ***BRAF* mutation (12)**      3.29                 1.14--9.54                  **0.028**               1.41   0.20--9.90    0.728       1.00   0.20--5.07    0.997
  **Ezrin low *MSS (117)***     Reference category   Reference category          Reference category                                                            
  **Ezrin low *MSI (18)***      0.34                 0.10--1.15                  0.083                   0.00   0.00-.000     0.986       0.78   0.09--6.66    0.824
  **Ezrin high *MSS (19)***     0.98                 0.37--2.64                  0.975                   5.68   1.53--21.12   **0.01**    2.76   0.76--1.01    0.124
  **Ezrin high *MSI(19)***      0.76                 0.26--2.21                  0.619                   3.19   0.61--16.74   0.17        3.01   0.78--11.66   0.110

Discussion {#sec014}
==========

Stage II CRC patients possess a treatment challenge, because current diagnostic methods do not enable their accurate risk stratification. The purpose of this study was to test, whether analysis of ezrin, a promising prognostic marker, together with microsatellite instability and *BRAF* mutation status could be used for prognostication. Indeed, our results show ezrin as an independent prognostic marker for disease-specific survival in stage II CRC, and indicate this correlation to be further strengthened by concomitant microsatellite instability testing.

Previous studies by others and us have indicated an association between ezrin expression and CRC outcome. The earlier studies have been carried out with mixed cohorts, including various disease stages, which can lead to inaccurate conclusions. However, we are not aware of any studies that would have specifically focused on ezrin expression in stage II CRC. The current results indicate that tumors with high ezrin expression possess adverse biological features already at a stage, when the cancer has not yet disseminated. Importantly, as demonstrated by this study, these features are not associated with tumor location, histological grade, vascular invasion or other outcome-related clinicopathological features. Our results do not clarify the mechanism, by which ezrin may be linked with oncogenic properties. One explanation is that ezrin expression provides an advantage for the disseminating cells early on during metastatic seeding. Indeed, some previous studies have indicated a role for ezrin in this process \[[@pone.0185436.ref032],[@pone.0185436.ref033]\]. Interestingly, ezrin turned out to be a stronger DSS predictor than any of the clinipathological factors, apart from tumor perforation.

Ezrin expression is linked to the activity of several oncogenic signaling cascades. Ezrin can act both as a regulator and/or a down-stream target in several signaling pathways, including *Src*, *Akt*-*PI3K* and *PKA*, and these associations have been suggested to be of importance in ezrin's oncogenic properties \[[@pone.0185436.ref034],[@pone.0185436.ref035],[@pone.0185436.ref036]\]. Here, we found that ezrin expression correlated with *BRAF* mutation status; high ezrin immunoreactivity being significantly more common in *BRAF V60*0E than *BRAF wild-type* tumors. This is a novel finding, there are no previous reports that would have linked ezrin with *BRAF*. Even if the specific mechanism of the connection between these two genes is unknown, the association of both high ezrin expression and BRAF mutation with the activity of several oncogenic signaling pathways might partly explain this interesting finding.

In this study, *MSI* status alone did not correlate with survival, although the superior prognosis of patients with *MSI* CRC over *MSS* tumors has been demonstrated earlier in many studies \[[@pone.0185436.ref037],[@pone.0185436.ref038],[@pone.0185436.ref013],[@pone.0185436.ref039],[@pone.0185436.ref021]\]. However, the combination of ezrin expression with *MSI* status stratified the patients to prognostic groups, in which patients with *MSS* and high ezrin expression had the shortest DSS and patients with *MSI* and low ezrin expression had the best DSS (log-rank test, p = 0.007). This correlation is of interest as high ezrin expression was significantly more infrequent in *MSS* tumors than *MSI* tumors. Why the prognostic role of ezrin is especially pronounced in *MSS* tumors awaits further studies.

With this university hospital area based cohort we could confirm earlier findings related to microsatellite instability and *BRAF* mutation status. Mucinous histology and poor differentiation grade were associated with *MSI*, which is in accordance with *MSI* high phenotype \[[@pone.0185436.ref040]\]. In the current study, about a fifth of the tumors were *MSI* high, and *MSI* high tumors were significantly more commonly right-sided, as reported previously for stage II tumors \[[@pone.0185436.ref037],[@pone.0185436.ref013]\]. Sidedness in itself, however does not justify patient selection for possible adjuvant therapy in stage II CRC \[[@pone.0185436.ref041]\].

In the current study, 84% of *BRAF mutated* tumors were *MSI*, whereas most *BRAF wild ty*pe tumors were *MSS*. *BRAF* mutation was also significantly linked to overall survival, the HR for mortality being 3.29 (95%CI \[1.14--9.54\], p = 0.028). Similar results have also been reported in previous studies, showing *BRAF* mutation to associate with increased mortality due to CRC \[[@pone.0185436.ref021],[@pone.0185436.ref042]\]. There is evidence that *MSI* phenotype may compensate the poor prognostic effect of *BRAF* mutation \[[@pone.0185436.ref043]\], but this issue remains controversial \[[@pone.0185436.ref044]\]. *BRAF* mutation is also reported to rule out Lynch syndrome \[[@pone.0185436.ref017]\], which may be of help to the clinicians in counseling the patients and their families.

At the time-point the patients were treated, *MSI*-status was not routinely tested among stage II patients. Altogether, 37% of the patients had received adjuvant chemotherapy, according to possible high-risk factors including preoperative obstruction or perforation, vascular invasion, poor differentiation grade and T4-stage and depending on their overall health, general health and patient preference. Patients with *MSI* tumors are reported not to gain benefit from fluorouracil-based adjuvant chemotherapy \[[@pone.0185436.ref013],[@pone.0185436.ref045]\]. This concerns especially stage II colorectal cancer patients, while there are conflicting results concerning stage III patients \[[@pone.0185436.ref046]\].

In conclusion, our study found a correlation between ezrin expression and DSS in stage II CRC, and this correlation was further strengthened by microsatellite instability analysis. Of the different tumor categories, DSS was longest in patients presenting with MSI / low ezrin tumors and shortest in *MSS* / high ezrin tumors. These results imply that ezrin staining can provide important prognostic information for estimating stage II patients' individual risk of disease recurrence and progression.
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